Sarepta Plunged After Adverse Event Forces Trial Halt in the UK Post author:Sam Post published:February 11, 2018 Post category:BioPharma But the biotech swiftly indicated that it doesn’t expect the halt to last for long. Source: BioSpace You Might Also Like FDA Expands Bristol-Myers Squibb’s Opdivo Dosing Schedule March 5, 2018 Heads Up Tesaro: AstraZeneca PLC, Merck & Co.'s Ovarian Cancer Drug Just Got Expanded Use From the FDA August 17, 2017 Medtronic RESOLUTE ONYX 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year May 17, 2017
Heads Up Tesaro: AstraZeneca PLC, Merck & Co.'s Ovarian Cancer Drug Just Got Expanded Use From the FDA August 17, 2017
Medtronic RESOLUTE ONYX 2.0 mm Clinical Study Meets Primary Endpoint in Extra-Small Vessels at One-Year May 17, 2017
